Share This

Related Topics News -

     
 Title only   |   Print 
     
復宏漢霖旗下HLX22美國臨床試驗申請獲批

2024-05-06T  
復宏漢霖首季營業收入按年增長35.5%

2024-04-29T  
復宏漢霖:漢曲優獲FDA批准用於乳腺癌輔助治療等

2024-04-26T  
復宏漢霖HLX6018注射液臨床研究完成首例受試者給藥

2024-04-23T  
復宏漢霖HLX53聯合漢斯狀及漢貝泰治療肝細胞癌獲批臨床試驗

2024-04-17T  
復宏漢霖生物類似藥HLX14三期臨床研究達到主要研究終點

2024-04-05T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.